<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42048">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558959</url>
  </required_header>
  <id_info>
    <org_study_id>ZYYYMedOncoBIL01</org_study_id>
    <nct_id>NCT02558959</nct_id>
  </id_info>
  <brief_title>Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer</brief_title>
  <official_title>Effect of Second-line Irinotecan and Capecitabine Versus Irinotecan Alone in Advanced Biliary Tract Cancer Patients Progressed After First-line Gemcitabine and Cisplatin: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <brief_summary>
    <textblock>
      This study is designed to investigate the effect of second-line irinotecan and capecitabine
      versus irinotecan alone for gemcitabine and cisplatin refractory advanced biliary tract
      cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>within 1 year</time_frame>
    <description>PFS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>within 1 year</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Biliary Tract Neoplasms</condition>
  <arm_group>
    <arm_group_label>Irinotecan and Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irinotecan 180mg/m2 d1, capecitabine 1000mg/m2 bid d1-10, q2w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>capecitabine 1000mg/m2 bid d1-14, q3w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>Irinotecan and Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Irinotecan and Capecitabine</arm_group_label>
    <arm_group_label>Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed advanced biliary tract cancer who had
             experienced progression during first-line gemcitabine and cisplatin

          -  Age 18 years or older

          -  Measurable reference cancer site(s) confirmed with computed tomography (CT) or
             magnetic resonance imaging (MRI)

          -  Karnofsky performance status (KPS) of at least 70%

          -  Adequate renal function, adequate hepatic function, adequate bone marrow function

        Exclusion Criteria:

          -  The presence of any severe concomitant disease that could interrupt the planned
             treatment

          -  Intractable pain

          -  Hypersensitivity to study drugs

          -  Serious cardiovascular disease

          -  If female, pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>First affiliated hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 29, 2015</lastchanged_date>
  <firstreceived_date>September 21, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Weijia Fang</investigator_full_name>
    <investigator_title>Director of Cancer Biotherapy Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
